RBC Capital Maintains Outperform on Avid Bioservices, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge has maintained an 'Outperform' rating on Avid Bioservices (NASDAQ:CDMO) and raised the price target from $8 to $12.
September 10, 2024 | 2:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has increased its price target for Avid Bioservices from $8 to $12, maintaining an 'Outperform' rating. This suggests a positive outlook for the company's stock.
The increase in price target from $8 to $12 by RBC Capital indicates a strong positive sentiment towards Avid Bioservices' future performance. The 'Outperform' rating suggests that the stock is expected to perform better than the market average, which is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100